Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.
New research has filled in missing links between gene variants that have been implicated in disease through genome-wide association studies and how the variants drive disease pathology. The research involved using induced pluripotent stem cells derived from healthy donors and transforming them into macrophages. These were then exposed to 24 different stimuli mimicking infection and inflammation, and the gene expression profiles assessed six and 24 hours later, to see which genes were turned on or off in response.
Chengdu Kanghong Pharmaceutical Co. Ltd. has described orexin OX2 receptor (OX2R; HCRTR2) antagonists reported to be useful for the treatment of secondary insomnia and major depression.
Alicorn Pharmaceutical Co. Ltd. has divulged S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Merck KGaA has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase-binding moiety covalently bonded to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Les Laboratories Servier SAS and Vernalis (R&D) Ltd. have disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, immunological and genetic disorders.
Gilead Sciences Inc. recently discussed the discovery of emvistegrast (GS-1427), a potent, selective, once-daily oral α4β7 integrin inhibitor currently in phase II trials for the treatment of inflammatory bowel disease (IBD) (NCT06290934).
Minovia Therapeutics Ltd. has announced a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers.
BMS-986470 is a potentially first-in-class molecular glue dual degrader, targeting zinc finger and BTB domain containing 7A (ZBTB7A) and widely interspaced zinc finger protein (WIZ). Bristol Myers Squibb Inc. recently presented details on the discovery of BMS-986470, which is now in phase I studies for the treatment of sickle cell disease (SCD) (NCT06481306).
RSS
